Increased expression of a disintegrin and metalloprotease-9 in hepatocellular carcinoma: Implications for tumor progression and prognosis

Japanese Journal of Clinical Oncology

Volumn 40, Issue 7, 2010, Pages 645-651

  Tao, KaiShan ^a   Qian, NianSong ^a   Tang, Yu ^a   Ti, Zhenyu ^a   Song, WenJie ^a   Cao, DaYong ^a   Dou, KeFeng ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

A disintegrin and metalloprotease; Hepatocellular carcinoma; Prognosis

Indexed keywords

DISINTEGRIN; GELATINASE B;

ADULT; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; FEMALE; HEPATIC VEIN; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PORTAL VEIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SURVIVAL RATE;

ADAM PROTEINS; ADULT; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77954442704     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq030     Document Type: Article

References (27)

1. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6:674-87.
2. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-46.
3. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107-16.
4. Maheshwari S, Sarraj A, Kramer J, El-Serag HB. Oral contraception and the risk of hepatocellular carcinoma. J Hepatol 2007;47:506-13.
5. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003;17:7-30.
6. Normanno N, Bianco C, Strizzi L, Mancino M, Maiello MR, De Luca A, et al. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets 2005;6:243-57.
7. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2-16.
8. O'Shea C, McKie N, Buggy Y. Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer 2003;105:754-61.
9. Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, Van Heek NT, Rosty C, et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 2003;162:1151-62.
10. Peduto L, Reuter VE, Shaffer DR. Critical function for ADAM9 in mouse prostate cancer. Cancer Res 2005;65:9312-9.
11. Shintani Y, Higashiyama S, Ohta M. Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res 2004;64:4190-6.
12. Fritzsche FR, Wassermann K, Jung M, Tölle A, Kristiansen I, Lein M, et al. ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression. BMC Cancer 2008;8:179.
13. Ishak KG, Anthony PP, Sobin LH. Nonepithelial tumors. In: Ishak KG, editor. Histological Typing of Tumors of the Liver. World Health Organization International Classification of Tumors. Berlin: Springer 1994;22-7.
14. Wittekind C. Pitfalls in the classification of liver tumors. Pathologe 2006;27:289-93.
15. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007; 25:2586-93.
16. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 2008;26:2707-16.
17. Grützmann R, Lüttges J, Sipos B, Ammerpohl O, Dobrowolski F, Alldinger I, et al. ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer 2004;90:1053-8.
18. Fritzsche FR, Jung M, Tölle A, Wild P, Hartmann A, Wassermann K, et al. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol 2008;54:1097-108.
19. Mazzocca A, Coppari R, De Franco R. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res 2005;65:4728-38.
20. Huovila AP, Turner AJ, Pelto-Huikko M, Karkkainen I, Ortiz RM. Shedding light on ADAM metalloproteinases. Trends Biochem Sci 2005;30:413-22.
21. Izumi Y, Hirata M, Hasuwa H. A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J 1998;17:7260-72.
22. Carl-McGrath S, Lendeckel U, Ebert M, Roessner A, Rocken C. The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol 2005;26:17-24.
23. Le Pabic H, Bonnier D, Wewer UM. ADAM12 in human liver cancers: TGF-beta-regulated expression in stellate cells is associated with matrix remodeling. Hepatology 2003;37:1056-66.
24. Grutzmann R, Foerder M, Alldinger I. Gene expression profiles of microdissected pancreatic ductal adenocarcinoma. Virchows Arch 2003;443:508-17.
25. Alldinger I, Dittert D, Peiper M. Gene expression analysis of pancreatic cell lines reveals genes overexpressed in pancreatic cancer. Pancreatology 2005;5:370-9.
26. Zigrino P, Mauch C, Fox JW, Nischt R. Adam-9 expression and regulation in human skin melanoma and melanoma cell lines. Int J Cancer 2005;116:853-9.
27. Chin K, DeVries S, Fridlyand J. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006;10:529-41.